Weng Jiayi*, Vishal G. Shelat

Jiayi et al. J Clin Transl Res 2022; 8(2):1

Published online: Febuary 2, 2022


Background: Radical cholecystectomy (RC) is recommended for Gallbladder cancer (GbC) patients with resectable T1b or higher stage. Traditionally, open RC is preferred over minimally invasive approach. Robotic surgery is increasingly gaining popularity and there are reports of robotic radical cholecystectomy (RRC) for GbC. RRC is still new and mostly performed in high volume centres with access to robotic technology.
Aim: This study aims to review the current literature on the safety and feasibility of RRC for GbC.
Methods: We performed a systematic review of RRC for GbC using PubMed and Embase until December 2020. The primary endpoint was major complications, while the secondary endpoints were conversion to open, R0 resection and early recurrence.
Results: Seven studies with 74 patients were included. Overall, 4 patients (5.41%) required open conversion. Five out of 74 patients (6.76%) experienced post-operative complications. There was no post-operative mortality. Among the patients with surgical margins reported (n=63), 61 patients had negative margins (96.8%) and only two patients had positive margins. Two-year survival outcomes were reported as 60.5-100%.
Relevance for patients: This is the first review that summarizes the current evidence on RRC for GbC. The endpoints suggest that RRC is feasible and safe in selected patients and when done in experienced centres. Understanding the strengths and limitations of RRC compared to other established therapeutic options may potentially aid surgeons in formulating the optimal treatment plan for GbC patients.


DOI: http://dx.doi.org/10.18053/jctres.08.202202.001

Author affiliation

1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2. Department of General Surgery, Tan Tock Seng Hospital, Singapore

*Corresponding author
Weng Jiayi
Yong Loo Lin School of Medicine, National University of Singapore , 10 Medical Dr, Singapore 117597
Tel: +65 98592965
Email: wengjiayi28@gmail.com

Handling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China


Full text PDF
Review process file (167.9 KB)